Yearly Archives: 2017

­

Quark Pharmaceuticals, Inc. to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual RNAi China Conference

October 9th, 2017|

FREMONT, Calif., Oct. 9, 2017 Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, is delivering an oral presentation at the 6th Annual RNAi China Conference in Jiangsu.

The presentation will summarize the preclinical efficacy data for inhaled small interfering RNA (siRNA) against an undisclosed […]

Quark Pharmaceuticals RNAi Drug Succeeds in Phase 2 Study to Prevent Acute Kidney Injury Following Cardiac Surgery

July 27th, 2017|

QPI 1002 Meets Primary & Multiple Secondary Endpoints
A statistically significant reduction in AKI incidence following cardiac surgery was demonstrated
First multicenter Phase 2 clinical study with an investigational drug for the prevention of AKI to meet primary endpoint
QPI-1002 appears to be well tolerated with no safety issues identified

Fremont, CA – July 27, 2017 – Today, Quark […]

Scientific Writer

March 8th, 2017|

 

Full-time or Contractor
Experienced in writing study reports for drug discovery programs including in vitro and in vivo Pharmacology studies
Reporting to CSO and working closely with Project Directors
M.Sc. in Biology or higher with at least 3 years industry experience
Experience in preparation of IND packages – advantage
Proficient in English (level of mother tongue)